封面
市場調查報告書
商品編碼
1594613

基於腫瘤學的體內 CRO 市場:按服務、適應症和最終用戶分類 - 全球預測 2025-2030 年

Oncology Based In-Vivo CRO Market by Services (Biomarker Development, Clinical Trial Management, Pharmacokinetics Studies), Indication (Hematological Malignancies, Rare Cancer, Solid Tumor), End-User - Global Forecast 2025-2030

出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年,基於腫瘤的體內CRO市場估值為12.7億美元,預計到2024年將達到14.1億美元,複合年成長率為11.34%,到2030年將達到27億美元。

基於腫瘤學的體內 CRO(合約委外研發機構)為臨床前測試提供廣泛的服務,重點是對新型癌症治療的體內全面評估。更準確地說,這些 CRO 進行評估癌症藥物的功效、安全性和藥物動力學的研究,促進藥物開發的關鍵步驟。這種需求源於對個人化醫療日益成長的需求以及對有效癌症治療的持續追求。它具有廣泛的應用,包括藥物發現、轉化研究和監管提交,並被製藥公司、研究機構、生物技術公司和其他最終用戶使用。推動該市場的主要成長要素包括全球癌症發生率上升、腫瘤學研究投資增加以及動物建模技術進步。

主要市場統計
基準年[2023] 12.7億美元
預測年份 [2024] 14.1億美元
預測年份 [2030] 27億美元
複合年成長率(%) 11.34%

隨著人工智慧和巨量資料分析的整合,現代商機不斷湧現,以增強臨床結果的預測模型並簡化藥物開發流程。與學術界和新興生物技術公司合作進行創新且具有成本效益的試驗設計也是一個有前途的途徑。然而,這個市場面臨著嚴格的監管要求和動物測試的道德問題等挑戰,這使得測試過程變得緩慢和複雜。此外,與體外模型的競爭以及相關人員因成本限制而不願意是主要障礙。

市場開拓可以集中於開發更具預測性和人性化的體內模型、引入數位生物標記以及提高從動物實驗中收集的資料的準確性。公司應考慮投資能夠提高結果可重複性並降低流失率的技術。該市場的動態本質強調對新的科學進步和監管變化的適應能力。尋求發展的公司應優先考慮建立策略夥伴關係、投資個人化測試模型並遵守不斷發展的全球標準,以便在這個快速發展的領域中獲得競爭優勢。

市場動態:針對快速發展的基於腫瘤學的體內 CRO 市場揭示的關鍵市場洞察

基於腫瘤學的體內 CRO 市場正因供需的動態交互作用而轉變。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險,同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 癌症發生率增加和有效藥物發現的需求
    • 對最佳化和高效的癌症臨床試驗活動的需求日益成長
    • 政府鼓勵個人化醫療的舉措
  • 市場限制因素
    • 資料安全和隱私問題
  • 市場機會
    • 透過資料分析和人工智慧,基於腫瘤學的體內技術取得進展
    • 擴大腫瘤學 CRO 服務以開發生物標記
  • 市場挑戰
    • 癌症臨床試驗中監管合規性的限制

波特五力:駕馭腫瘤體內 CRO 市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢、解決弱點並避免潛在的挑戰,以確保更強大的市場地位。

PESTLE分析:了解基於腫瘤學的體內 CRO 市場的外部影響

外部宏觀環境因素在塑造基於腫瘤的體內 CRO 市場的績效動態方面發揮關鍵作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素,公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化,並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解基於腫瘤學的體內 CRO 市場的競爭格局

基於腫瘤學的體內 CRO 市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢,為供應商提供了製定策略決策所需的洞察力,使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣基於腫瘤學的體內 CRO 市場供應商績效評估

FPNV 定位矩陣是評估基於腫瘤的體內 CRO 市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商,從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商,並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議,為腫瘤體內 CRO 市場的成功指明道路

對於旨在加強其在全球市場的影響力的公司來說,基於腫瘤學的體內 CRO 市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標,公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰,利用新的商機,並取得長期成功。

本報告對市場進行了全面分析,涵蓋關鍵重點領域:

1. 市場滲透率:詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓:辨識新興市場的成長機會,評估現有領域的擴張潛力,並提供未來成長的策略藍圖。

3. 市場多元化:分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報:徹底分析競爭格局,檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新:重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題,以幫助相關人員做出明智的決策:

1.目前的市場規模和未來的成長預測是多少?

2. 哪些產品、區隔市場和地區提供最佳投資機會?

3.塑造市場的主要技術趨勢和監管影響是什麼?

4.主要廠商的市場佔有率和競爭地位如何?

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼?

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 癌症發生率增加以及有效新藥發現的需求
      • 對最佳化和高效的腫瘤臨床試驗活動的需求日益成長
      • 政府鼓勵個人化醫療的舉措
    • 抑制因素
      • 資料安全和隱私問題
    • 機會
      • 利用資料分析和人工智慧的基於腫瘤學的體內技術的進展
      • 擴大腫瘤學 CRO 服務以開發生物標記
    • 任務
      • 腫瘤學試驗中監管合規性的局限性
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章基於腫瘤的體內 CRO 市場:按服務分類

  • 生物標記開發
  • 臨床試驗管理
  • 藥物動力學研究
  • 臨床前研究

第7章基於腫瘤的體內 CRO 市場(按適應症)

  • 造血系統惡性
  • 罕見癌症
  • 固態腫瘤

第8章基於腫瘤學的體內 CRO 市場:按最終用戶分類

  • 學術研究所
  • 生技公司
  • 製藥公司

第9章美洲基於腫瘤的體內 CRO 市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區以腫瘤為基礎的體內 CRO 市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲基於腫瘤的體內 CRO 市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣,2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Altogen Labs
  • Cellvax, SAS
  • Charles River Laboratory
  • Crown Bioscience
  • Cyagen Biosciences
  • Evotec SE
  • Explicyte by Immusmol SAS Company
  • Icon PLC
  • Imavita
  • IVRS AB
  • Laboratory Corporation of America Holdings
  • Melior Discovery
  • Noble Life Sciences
  • Pharmaron
  • Pharmatest Services
  • Reaction Biology by Copeba
  • Redoxis AB
  • Taconic Biosciences, Inc.
  • The Jackson Laboratory
  • XenTech
Product Code: MRR-FF012EDC38C0

The Oncology Based In-Vivo CRO Market was valued at USD 1.27 billion in 2023, expected to reach USD 1.41 billion in 2024, and is projected to grow at a CAGR of 11.34%, to USD 2.70 billion by 2030.

The scope of oncology-based in-vivo CROs (Contract Research Organizations) involves providing a wide range of services for preclinical studies, focusing on the comprehensive assessment of novel cancer therapies in living organisms. Precisely, these CROs conduct studies that evaluate the efficacy, safety, and pharmacokinetics of oncology drugs, facilitating a critical step in drug development. Their necessity stems from the increasing demand for personalized medicine and the relentless pursuit of effective cancer treatments. Applications are versatile, including drug discovery, translational research, and regulatory submissions, serving end-uses in pharmaceutical companies, research institutions, and biotech firms. Key growth factors driving this market include the rising incidence of cancer worldwide, growing investments in oncology research, and technological advancements in animal modeling.

KEY MARKET STATISTICS
Base Year [2023] USD 1.27 billion
Estimated Year [2024] USD 1.41 billion
Forecast Year [2030] USD 2.70 billion
CAGR (%) 11.34%

Latest opportunities are emerging with the integration of artificial intelligence and big data analytics, which enhance the predictive modeling of clinical outcomes and streamline drug development processes. Leveraging collaborations with academia and emerging biotech for innovative, cost-effective study designs is also a promising avenue. However, the market faces challenges such as stringent regulatory requirements and ethical concerns related to animal testing, which can delay and complicate study processes. Additionally, competition from in-vitro models and reluctance from stakeholders due to cost constraints are substantial barriers.

Market innovations could focus on developing more predictive and humane in-vivo models, incorporating digital biomarkers, and enhancing the precision of data gathered from animal studies. Companies should consider investing in technologies that improve the reproducibility of results and reduce attrition rates. The nature of this market is dynamic, with a strong emphasis on the adaptability to new scientific advancements and regulatory changes. Businesses aiming for growth should prioritize forming strategic partnerships, investing in personalized study models, and ensuring compliance with evolving global standards to secure a competitive advantage in this rapidly evolving field.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Oncology Based In-Vivo CRO Market

The Oncology Based In-Vivo CRO Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing incidence of cancer and need for effective drug discovery
    • Rising need for optimized and efficient oncology clinical trial activities
    • Government initiatives encouraging personalized medicine
  • Market Restraints
    • Concerns associated with data security and privacy
  • Market Opportunities
    • Advancements in oncology-based in-vivo technologies with data analytics and AI
    • Expansion of oncology CRO services for biomarker development
  • Market Challenges
    • Limitations of regulatory compliance of oncology trials

Porter's Five Forces: A Strategic Tool for Navigating the Oncology Based In-Vivo CRO Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Oncology Based In-Vivo CRO Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Oncology Based In-Vivo CRO Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Oncology Based In-Vivo CRO Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Oncology Based In-Vivo CRO Market

A detailed market share analysis in the Oncology Based In-Vivo CRO Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Oncology Based In-Vivo CRO Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Oncology Based In-Vivo CRO Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Oncology Based In-Vivo CRO Market

A strategic analysis of the Oncology Based In-Vivo CRO Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Oncology Based In-Vivo CRO Market, highlighting leading vendors and their innovative profiles. These include Altogen Labs, Cellvax, SAS, Charles River Laboratory, Crown Bioscience, Cyagen Biosciences, Evotec SE, Explicyte by Immusmol SAS Company, Icon PLC, Imavita, IVRS AB, Laboratory Corporation of America Holdings, Melior Discovery, Noble Life Sciences, Pharmaron, Pharmatest Services, Reaction Biology by Copeba, Redoxis AB, Taconic Biosciences, Inc., The Jackson Laboratory, and XenTech.

Market Segmentation & Coverage

This research report categorizes the Oncology Based In-Vivo CRO Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Services, market is studied across Biomarker Development, Clinical Trial Management, Pharmacokinetics Studies, and Preclinical Studies.
  • Based on Indication, market is studied across Hematological Malignancies, Rare Cancer, and Solid Tumor.
  • Based on End-User, market is studied across Academic & Research Institutes, Biotechnology Companies, and Pharmaceutical Companies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidence of cancer and need for effective drug discovery
      • 5.1.1.2. Rising need for optimized and efficient oncology clinical trial activities
      • 5.1.1.3. Government initiatives encouraging personalized medicine
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns associated with data security and privacy
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in oncology-based in-vivo technologies with data analytics and AI
      • 5.1.3.2. Expansion of oncology CRO services for biomarker development
    • 5.1.4. Challenges
      • 5.1.4.1. Limitations of regulatory compliance of oncology trials
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Oncology Based In-Vivo CRO Market, by Services

  • 6.1. Introduction
  • 6.2. Biomarker Development
  • 6.3. Clinical Trial Management
  • 6.4. Pharmacokinetics Studies
  • 6.5. Preclinical Studies

7. Oncology Based In-Vivo CRO Market, by Indication

  • 7.1. Introduction
  • 7.2. Hematological Malignancies
  • 7.3. Rare Cancer
  • 7.4. Solid Tumor

8. Oncology Based In-Vivo CRO Market, by End-User

  • 8.1. Introduction
  • 8.2. Academic & Research Institutes
  • 8.3. Biotechnology Companies
  • 8.4. Pharmaceutical Companies

9. Americas Oncology Based In-Vivo CRO Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Oncology Based In-Vivo CRO Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Oncology Based In-Vivo CRO Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Altogen Labs
  • 2. Cellvax, SAS
  • 3. Charles River Laboratory
  • 4. Crown Bioscience
  • 5. Cyagen Biosciences
  • 6. Evotec SE
  • 7. Explicyte by Immusmol SAS Company
  • 8. Icon PLC
  • 9. Imavita
  • 10. IVRS AB
  • 11. Laboratory Corporation of America Holdings
  • 12. Melior Discovery
  • 13. Noble Life Sciences
  • 14. Pharmaron
  • 15. Pharmatest Services
  • 16. Reaction Biology by Copeba
  • 17. Redoxis AB
  • 18. Taconic Biosciences, Inc.
  • 19. The Jackson Laboratory
  • 20. XenTech

LIST OF FIGURES

  • FIGURE 1. ONCOLOGY BASED IN-VIVO CRO MARKET RESEARCH PROCESS
  • FIGURE 2. ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ONCOLOGY BASED IN-VIVO CRO MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ONCOLOGY BASED IN-VIVO CRO MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ONCOLOGY BASED IN-VIVO CRO MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ONCOLOGY BASED IN-VIVO CRO MARKET DYNAMICS
  • TABLE 7. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY BIOMARKER DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CLINICAL TRIAL MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY PHARMACOKINETICS STUDIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY PRECLINICAL STUDIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY RARE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SOLID TUMOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. ONCOLOGY BASED IN-VIVO CRO MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 148. ONCOLOGY BASED IN-VIVO CRO MARKET, FPNV POSITIONING MATRIX, 2023